Equities Analysts Issue Forecasts for Adaptimmune Therapeutics plc’s Q2 2022 Earnings (NASDAQ:ADAP)

Adaptimmune Therapeutics plc (NASDAQ:ADAP – Get Rating) – Investment analysts at SVB Leerink upped their Q2 2022 EPS estimates for Adaptimmune Therapeutics in a research report issued to clients and investors on Monday, May 9th. SVB Leerink analyst J. Chang now forecasts that the biotechnology company will earn ($0.21) per share for the quarter, up from their previous forecast of ($0.27). SVB Leerink currently has a “Market Perform” rating and a $3.00 price objective on the stock. SVB Leerink also issued estimates for Adaptimmune Therapeutics’ Q3 2022 earnings at ($0.22) EPS, Q4 2022 earnings at ($0.23) EPS, FY2022 earnings at ($0.99) EPS and FY2023 earnings at ($0.55) EPS.

Adaptimmune Therapeutics (NASDAQ:ADAP – Get Rating) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.04). Adaptimmune Therapeutics had a negative net margin of 1,836.31% and a negative return on equity of 76.84%. During the same quarter in the previous year, the firm earned ($0.24) earnings per share.

Several other research firms have also weighed in on ADAP. StockNews.com started coverage on shares of Adaptimmune Therapeutics in a report on Thursday, March 31st. They set a “hold” rating on the stock. Zacks Investment Research downgraded shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 15th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.92.

Shares of ADAP opened at $1.41 on Thursday. The firm has a market cap of $221.18 million, a PE ratio of -1.31 and a beta of 2.07. The company’s fifty day moving average is $1.92 and its two-hundred day moving average is $3.05. Adaptimmune Therapeutics has a fifty-two week low of $1.26 and a fifty-two week high of $6.86.

Institutional investors have recently made changes to their positions in the stock. Wells Fargo & Company MN raised its holdings in shares of Adaptimmune Therapeutics by 34.3% in the second quarter. Wells Fargo & Company MN now owns 15,670 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 3,999 shares during the last quarter. US Bancorp DE lifted its position in Adaptimmune Therapeutics by 403.0% during the third quarter. US Bancorp DE now owns 5,729 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 4,590 shares during the period. Personal CFO Solutions LLC lifted its position in Adaptimmune Therapeutics by 19.7% during the third quarter. Personal CFO Solutions LLC now owns 36,388 shares of the biotechnology company’s stock worth $188,000 after purchasing an additional 6,000 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its position in Adaptimmune Therapeutics by 13.6% during the fourth quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 69,140 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 8,292 shares during the period. Finally, Hunter Associates Investment Management LLC raised its stake in Adaptimmune Therapeutics by 81.8% during the first quarter. Hunter Associates Investment Management LLC now owns 20,000 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 9,000 shares in the last quarter.

Adaptimmune Therapeutics Company Profile (Get Rating)

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets.

See Also